This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

Anemia is a significant side effect of cancer and its therapies and occurs with treatment in 13% to 78% of patients with solid tumors and 30% to 40% of patients with lymphoma. In most cases, blood ...

April 6, 2005 — The U.S. Food and Drug Administration (FDA) announced in January revisions to safety labeling to advise healthcare professionals of the following changes: use of darbepoetin alfa ...

In a real-world study, UPCR decreased when darbepoetin alfa dose exceeded 60 μg in patients with diabetic kidney disease. Darbepoetin alfa treatment is associated with proteinuria lowering in a ...

Please provide your email address to receive an email when new articles are posted on . Vadadustat demonstrated the efficacy and cardiovascular safety for the treatment of anemia in adult patients ...

Pilot study to determine the effects of dronabinol on hot flash relief in breast cancer patients Background: Anemia occurring in cancer patients undergoing Chemotherapy and or Radiotherapy causes ...

Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint. Vadadustat has met its primary and ...

Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa' ~Patients with chronic kidney disease and anaemia set to gain~ India, Mumbai, 19th June 2014: Cipla, a global ...

BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...